Latest news with #PMBJP
New Indian Express
4 days ago
- Health
- New Indian Express
Red Cross Society to open Jan Aushadhi stores at all Andhra Pradesh govt general hospitals
VIJAYAWADA: In a move to make essential medicines more affordable and curb profiteering, the State government has permitted the Indian Red Cross Society (IRCS) to set up Jan Aushadhi medical stores in all 26 district Government General Hospitals (GGHs). The decision follows concerns raised by the Director of Medical Education (DME), who noted irregular pricing and profiteering at generic medicine shops in teaching hospitals. Many of these outlets, initially allotted to Self-Help Groups, are now reportedly operated by private individuals offering inconsistent discounts. The Jan Aushadhi outlets will operate under the Pradhan Mantri Bhartiya Jan Aushadhi Pariyojana (PMBJP), a Union government initiative that ensures quality generic medicines at affordable prices. The PMBJP model, overseen by the Department of Pharmaceuticals, Union Ministry of Chemicals & Fertilisers, sources medicines directly from manufacturers through a transparent tendering process. Drugs are sold at printed MRP with a fixed 15% margin, ensuring affordability and quality assurance. Hospital Development Societies, in consultation with the Roads and Buildings Department, will finalise lease rates for the Red Cross-operated outlets. The initiative is expected to regulate access to essential medicines statewide.
India.com
4 days ago
- Health
- India.com
West Bengal: Know How West Midnapore Residents Get Medicines At 90 % Discount Through Jan Aushadhi Kendras
Residents of West Bengal's West Midnapore district are increasingly benefiting from the Pradhan Mantri Bhartiya Janaushadhi Pariyojana (PMBJP), a flagship initiative of the Central government aimed at making quality medicines affordable and accessible for all. Under the scheme, Jan Aushadhi Kendras have been established in various parts of the district, offering essential medicines at discounts ranging from 50 per cent to 90 per cent. These outlets are proving to be a lifeline for many, especially those from economically weaker sections. The response from the public has been overwhelmingly positive. Locals said that the medicines available at the Kendras are not only affordable but also effective and reliable. Several such Kendras are already operational in West Midnapore, and there is growing demand for more to be opened in remote areas. Santu Ghosh, an operator of one of the Kendras, shared his experience with IANS. 'I've been running this shop for a year now. Initially, people were hesitant as they were unfamiliar with generic medicines. But after advertisements, the response has been very good. For instance, paracetamol costs just Rs 15 for 15 tablets here. Outside, it's much costlier. The scheme offers medicines at a 50 per cent to 90 per cent discount. I thank the Prime Minister for this initiative, which helps common people access quality medicines at such low prices.' Harvinder Singh, a regular customer, said: "I've been getting my medicines from here for some time now. It's really good. The quality is excellent,t and it's saving us a lot of money" Launched in November 2008 by the Department of Pharmaceuticals under the Ministry of Chemicals and Fertilisers, the PMBJP aims to provide quality generic medicines through Jan Aushadhi Kendras across India. The scheme has gained momentum under the leadership of Prime Minister Narendra Modi, with thousands of such Kendras now operating nationwide. To promote the use of generic medicines, March 7 is observed annually as 'Jan Aushadhi Diwas.' This year, a week-long campaign from March 1 to 7 featured events and awareness drives across the country, further encouraging people to make use of the Kendras.
Times of Oman
19-05-2025
- Health
- Times of Oman
From generic drugs to vaccines, Indian pharma industry is transforming lives worldwide
New Delhi: India has transformed itself into a global health leader in terms of affordability, innovation, and inclusivity over the past decade. India's pharmaceutical industry is a global giant ranking third in volume and 14th in value. It's the largest supplier of generic medicines providing 20 per cent of the world's supply and a key player in affordable vaccines. In 2023-24, the sector's turnover hit Rs 4,17,345 crore growing steadily at over 10 per cent annually for the past five years. For the common people, this means more medicines at lower prices, better healthcare and jobs in factories and labs across the country. From small towns to big cities, India's pharma growth is creating opportunities and saving lives. The government claims that its schemes are the backbone of this success. The Pradhan Mantri Bhartiya Janaushadhi Pariyojana (PMBJP) runs 15,479 Jan Aushadhi Kendras, offering generic medicines at prices up to 80 per cent lower than branded ones. A heart medicine that once cost Rs 500 might now cost Rs 100. The Production Linked Incentive (PLI) Scheme for Pharmaceuticals with Rs 15,000 crore, supports 55 projects to make high-end drugs like cancer and diabetes medicines right here in India. Another PLI scheme with Rs 6,940 crore focuses on raw materials like Penicillin G, reducing our need for imports. The PLI for Medical Devices backed by Rs 3,420 crore is boosting production of tools like MRI machines and heart implants. Then there's the Promotion of Bulk Drug Parks scheme with Rs 3,000 crore building mega hubs in Gujarat, Himachal Pradesh and Andhra Pradesh to make medicines cheaper and faster. The Strengthening of Pharmaceuticals Industry (SPI) Scheme with Rs 500 crore, funds research and upgrades labs, helping Indian companies compete globally. "These efforts mean medicines are made in India, for India and for the world keeping costs low and quality high," the government said in a statement. India's pharma sector supplies 55-60 per cent of UNICEF's vaccines, meeting 99 per cent of WHO's DPT (Diphtheria, Whooping cough and Tetanus) vaccine demand, 52 per cent for BCG (Bacillus Calmette-Guerin is a vaccine primarily used against TB), and 45 per cent for measles. From Africa to America, Indian vaccines save millions. At home, these schemes create jobs for young Indians, from factory workers to scientists. Foreign investors are pouring in with Rs 12,822 crore in 2023-24 alone, because they see India's potential. India welcomes 100 per cent foreign investment in medical devices and greenfield pharma projects, making India a hotspot for global companies. India's pharmaceutical sector is more than an industry; it's a lifeline. With schemes like PMBJP, PLI, and Bulk Drug Parks, the Modi government is ensuring no one is left behind when it comes to healthcare.
India Gazette
18-05-2025
- Health
- India Gazette
From generic drugs to vaccines, Indian pharma industry is transforming lives worldwide
New Delhi [India], May 18 (ANI): India has transformed itself into a global health leader in terms of affordability, innovation, and inclusivity over the past decade. India's pharmaceutical industry is a global giant ranking third in volume and 14th in value. It's the largest supplier of generic medicines providing 20 per cent of the world's supply and a key player in affordable vaccines. In 2023-24, the sector's turnover hit Rs 4,17,345 crore growing steadily at over 10 per cent annually for the past five years. For the common people, this means more medicines at lower prices, better healthcare and jobs in factories and labs across the country. From small towns to big cities, India's pharma growth is creating opportunities and saving lives. The government claims that its schemes are the backbone of this success. The Pradhan Mantri Bhartiya Janaushadhi Pariyojana (PMBJP) runs 15,479 Jan Aushadhi Kendras, offering generic medicines at prices up to 80 per cent lower than branded ones. A heart medicine that once cost Rs 500 might now cost Rs 100. The Production Linked Incentive (PLI) Scheme for Pharmaceuticals with Rs 15,000 crore, supports 55 projects to make high-end drugs like cancer and diabetes medicines right here in India. Another PLI scheme with Rs 6,940 crore focuses on raw materials like Penicillin G, reducing our need for imports. The PLI for Medical Devices backed by Rs 3,420 crore is boosting production of tools like MRI machines and heart implants. Then there's the Promotion of Bulk Drug Parks scheme with Rs 3,000 crore building mega hubs in Gujarat, Himachal Pradesh and Andhra Pradesh to make medicines cheaper and faster. The Strengthening of Pharmaceuticals Industry (SPI) Scheme with Rs 500 crore, funds research and upgrades labs, helping Indian companies compete globally. 'These efforts mean medicines are made in India, for India and for the world keeping costs low and quality high,' the government said in a statement. India's pharma sector supplies 55-60 per cent of UNICEF's vaccines, meeting 99 per cent of WHO's DPT (Diphtheria, Whooping cough and Tetanus) vaccine demand, 52 per cent for BCG (Bacillus Calmette-Guerin is a vaccine primarily used against TB), and 45 per cent for measles. From Africa to America, Indian vaccines save millions. At home, these schemes create jobs for young Indians, from factory workers to scientists. Foreign investors are pouring in with Rs 12,822 crore in 2023-24 alone, because they see India's potential. India welcomes 100 per cent foreign investment in medical devices and greenfield pharma projects, making India a hotspot for global companies. India's pharmaceutical sector is more than an industry; it's a lifeline. With schemes like PMBJP, PLI, and Bulk Drug Parks, the Modi government is ensuring no one is left behind when it comes to healthcare. From affordable medicines at Jan Aushadhi Kendras to vaccines reaching the world, India is building a healthier, self-reliant future. (ANI)
Time of India
12-05-2025
- Health
- Time of India
Medicine supply: HLL inks deal with Maldives govt
T'puram: HLL Lifecare signed a strategic partnership with the govt of Maldives for supply of essential medicines. State Trading Organization Plc (STO), a govt of Maldives enterprise responsible for the import and distribution of essential goods, signed the agreement with HLL under India's Pradhan Mantri Bhartiya Janaushadhi Pariyojana (PMBJP), a govt initiative aimed at providing affordable, high-quality medicines to the partnership ensures a continuous and affordable supply of essential medicines to every corner of the Maldives. Over the past year, the Maldives' health system faced challenges with frequent stock-outs of vital pharmaceuticals, disrupting patient care and placing significant strain on Aasandha, the national health insurance imports restored 99% of the availability of essential medicines by April, but short-term solutions alone cannot ensure sustainable access. This agreement with HLL turns emergency relief into a permanent supply solution. This history of collaboration gives STO confidence that HLL can meet its needs. TNN
